continu expect strong growth keytruda
gardasil drive merck out-performance maintain ow rate
adjust ep follow result rais ep
left ep unchang ms old vs new vs
ex-u keytruda first-lin lung cancer offer signific upsid keytruda
franchis sale ex-u keytruda repres sale even though
merck yet launch first-lin lung cancer chemo combo ex-u
market current ex-u keytruda sale includ monotherapi
addit keytruda indic help fuel strong global growth year
come potenti addit indic includ breast gastric hepatocellular
renal head neck variou adjuvant-stag cancer
world-wide effort elimin cervic cancer caus hpv via gender-
neutral vaccin help drive gardasil adopt global
action toward elimin cervic cancer sever countri
offer expand recommend june meet doug lowi
nation cancer institut spoke import mount world-wide
immun campaign hpv addit american cancer
societi nation cancer institut also endors goal
elimin cancer caus hpv effect gender-neutr vaccin
adolesc jul report gardasil growth assumpt explain
continu expect oper leverag pipelin clariti
pleas see report oper leverag ahoy detail
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
pt base base case ep target multipl
slight premium peer averag believ
bull case ep
bull case ep
keytruda surpris upsid immuno-oncolog competitor
disappoint ep forecast due higher-than-project keytruda
sale competitor lung cancer combo trial indic rel
weak lead higher keytruda peak sale opportun multipl
base case ep
base case ep
merck offer solid growth prospect includ potenti upsid consensu
driven keytruda gardasil keytruda sale expand off-set declin
franchis eg januvia patent cliff keytruda clinic trial
newsflow drive addit label expans global adopt gardasil step
bear case ep
bear case ep
keytruda gardasil disappoint drive lower profit expect
competitor trial outperform ep forecast due keytruda
rel keytruda upcom data readout
overweight merck base upon solid
long-term growth prospect attract
see upsid consensu driven
pipelin option diseas beyond
oncolog specif vaccin hiv
come focu next year
keytruda sale trend trial
immuno-oncolog news flow
competitor roch azn
extern busi develop
us commerci govern price
competitor dataset newsflow
risk achiev price
upsid risk pipelin surpris
competitor shortfal financi upsid
downsid risk key product problem
shortfal litig regulatori risk
exhibit revenu declin three franchis would come
price
price
compani data morgan stanley research estim thomson reuter valuat methodolog risk associ price target
referenc research report pleas contact client support follow us/canada hong kong latin
altern may contact invest repres morgan stanley research broadway attent research manag new
exhibit trade histor mean
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
